Inactivation of miR-34a by aberrant CpG methylation in Kazakh patients with esophageal carcinoma

Cui, X and Zhao, Z and Liu, D and Guo, T and Li, S and Hu, J and Liu, C and Yang, L and Cao, Y and Jiang, J and Liang, W and Liu, W and Li, S and Wang, L and Wang, L and Gu, W and Wu, C and Chen, Y and Li, F (2014) Inactivation of miR-34a by aberrant CpG methylation in Kazakh patients with esophageal carcinoma. Journal of Experimental and Clinical Cancer Research, 33 (1).

Preview	PDF Published Version Available under License : See the attached license file. Download (963kB) | Preview
	Plain Text (licence) Available under License : See the attached license file. Download (1kB)

Abstract

Background: Esophageal squamous cell carcinoma (ESCC) is an aggressive tumor with dismal prognosis and high incidence and mortality in Kazakh population. MiR-34a, a direct p53 target gene, possesses tumor-suppressive properties as they mediate apoptosis, cell cycle arrest, and senescence. The reduced expression of miR-34a by methylation in various cancers has been reported. Methods. To determine whether aberrant miR-34a methylation occurs in esophageal cancer, the DNA methylation of 23 CpGs sites in the miR-34a promoter was quantitatively analyzed in relation to the translation initiation site by MALDI -TOF mass spectrometry in 59 ESCC tissues and 34 normal tissues from the Kazakh population. Real-time PCR was used to detect the inhibition of miR-34a expression levels and to evaluate their association with methylation. Results: We found that miR-34a is more frequently methylated in ESCC (0.133 ± 0.040) than in controls (0.066 ± 0.045, P < 0.01). A nearly two-fold increase in miR-34a expression for the hypomethylated promoter was found in normal esophageal tissues than ESCC with hypermethylation (P <0.0001), pointing to a negative relationship between miR-34a CpG sites methylation and expression(r = -0.594, P = 0.042). The hypermethylation of miR-34a CpG-8.9 was associated with the advanced UICC stage III/IV of the esophageal cancers, and the hypermethylation of CpG-8.9 and CpG-5 of miR-34a was significantly correlated with lymph node metastasis. Conclusions: Our findings suggest that miR-34a is involved in the etiology of ESCC and that hypermethylated miR-34a is a potential biomarker for ESCC diagnosis and prognosis. Moreover, targeting miR-34a methylation by demethylating agents may offer a novel strategy for anticancer therapy of ESCC. © 2014 Cui et al.; licensee BioMed Central Ltd.

---

Share

Citation/Export:	Select format... Citation - Text Citation - HTML Endnote BibTex Dublin Core OpenURL MARC (ISO 2709) METS MODS EP3 XML Reference Manager Refer
Social Networking:	Share |

---

Details

Item Type:	Article
Status:	Published
Creators/Authors:	Creators Email Pitt Username ORCID Cui, X Zhao, Z Liu, D Guo, T Li, S Hu, J Liu, C Yang, L Cao, Y Jiang, J Liang, W Liu, W Li, S Wang, L Wang, L Gu, W Wu, C carywu@pitt.edu CARYWU Chen, Y Li, F
Date:	17 February 2014
Date Type:	Publication
Journal or Publication Title:	Journal of Experimental and Clinical Cancer Research
Volume:	33
Number:	1
DOI or Unique Handle:	10.1186/1756-9966-33-20
Schools and Programs:	School of Medicine > Pathology
Refereed:	Yes
Date Deposited:	02 Dec 2016 20:35
Last Modified:	02 Feb 2019 16:58
URI:	http://d-scholarship.pitt.edu/id/eprint/29594

---

Metrics

Monthly Views for the past 3 years

Plum Analytics

Altmetric.com

---

Actions (login required)

View Item